{"url_path":"/sec/pure/10-q/2026/item-1a","section_key":"item-1a","section_title":"Item 1A Risk Factors**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-03-17","source_url":"https://www.sec.gov/Archives/edgar/data/1006028/0001493152-26-010385-index.html","accession_number":"0001493152-26-010385","cik":"0001006028","ticker":"PURE","issuer_name":"PURE BIOSCIENCE, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1006028/0001493152-26-010385-index.html","primary_entity_key":"0001006028","primary_entity_name":"PURE BIOSCIENCE, INC."},"word_count":759,"has_tables":true,"body_markdown":"**Item\n1A. Risk Factors**\n\n** **\n\n*In\nevaluating us and our common stock, we urge you to carefully consider the risks and other information in this Quarterly Report on Form\n10-Q, including the risk factor included below, as well as the risk factors disclosed in Item 1A. to Part I of our Annual Report on Form\n10-K for the fiscal year ended July 31, 2025, which we filed with the SEC on October 29, 2025 (the “Form 10-K”). Other than\nthe risk factor included below, the risks and uncertainties described in “Item 1A — Risk Factors” of our Form 10-K\nhave not materially changed. Any of the risks discussed in this Quarterly Report on Form 10-Q, including the risk factor included below,\nor any of the risks disclosed in “Item 1A — Risk Factors” of our Form 10-K, as well as additional risks and uncertainties\nnot currently known to us or that we currently deem immaterial, could materially and adversely affect our results of operations, financial\ncondition or prospects.*\n\n \n\n**Risks\nRelated to Our Business and Industry**\n\n \n\n**As\na result of our historical lack of financial liquidity, we do not currently have sufficient working capital to fund our planned operations\nand may not be able to continue as a going concern.**\n\n \n\nWe\nhave a history of recurring losses, and as of January 31, 2026 we have incurred a cumulative net loss of $140,243,000. During the six\nmonths ended January 31, 2026, we recorded a net loss of $1,249,000 on recorded net revenue of $1,152,000. In addition, during the six\nmonths ended January 31, 206 we used $856,000 in operating activities resulting in a cash balance of $198,000 as of January 31, 2026.\nAs a result, our existing cash resources are not sufficient to meet our anticipated needs over the next twelve months from the date hereof,\nand we will need to raise additional capital to continue our operations and to implement our business plan, which capital may not be\navailable on acceptable terms or at all.\n\n \n\n23\n\n \n\n \n\nOur\ncapital requirements will depend on many factors, including, among others:\n\n \n\n \n●\nthe\nmarket acceptance of, and demand for, our products;\n\n \n \n \n\n \n●\nthe\ntiming and costs of executing our sales and marketing strategies;\n\n \n \n \n\n \n●\nour\nability to successfully complete the in-plant validation trials requested by potential customers and our ability to convert these\ntrials into customer orders for our products;\n\n \n \n \n\n \n●\nthe\ncosts and time required to obtain the necessary regulatory approvals for our products, including the required USDA approvals:\n\n \n \n \n\n \n●\nthe\nextent to which we invest in new testing and product development, including in-plant optimization trials;\n\n \n \n \n\n \n●\nthe\nextent to which our customers continue to place product orders as expected and expand their existing use of our products;\n\n \n \n \n\n \n●\nthe\ncost and time to satisfy unique customer requirements regarding validation trials or to support the value proposition and benefits\nof our products;\n\n \n \n \n\n \n●\nthe\ntiming of vendor payments and the collection of receivables, among other factors affecting our working capital;\n\n \n \n \n\n \n●\nour\nability to control the timing and amount of our operating expenses, including the costs to attract and retain personnel with the\nskills required to implement our business plan; and\n\n \n \n \n\n \n●\nthe\ncosts to file, prosecute and defend our intellectual property rights.\n\n \n\nThe\nabove factors, along with our history and near term forecast of incurring net losses and negative operating cash flows, raise substantial\ndoubt about our ability to continue as a going concern. If we do not obtain additional capital from external sources, we will not have\nsufficient working capital to fund our planned operations or be able to continue as a going concern. We cannot assure you that additional\nfinancing will be available when needed or that, if available, we can obtain financing on terms favorable to us or to our stockholders.\nIf we raise additional funds from the issuance of equity securities, substantial dilution to our existing stockholders would likely result.\nIf we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well\nas covenants and specific financial ratios that may restrict our ability to operate our business. Further, any contracts or license arrangements\nwe enter into to raise funds may require us to relinquish our rights to our products or technology, and we cannot assure you that we\nwill be able to enter into any such contracts or license arrangements on acceptable terms, or at all. Having insufficient funds may require\nus to delay or scale back our marketing, distribution and other commercialization activities or cease our operations altogether."}